The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

EGFR+ Lung Cancer MORE >>

Adding bevacizumab to erlotinib significantly improved progression-free survival compared with erlotinib alone in patients with EGFR-positive, advanced nonsquamous non–small cell lung cancer, suggesting the combination may have the potential to become standard of care for this patient population.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.